ESG

ESG, SRI, Equities, Fixed Income

The complexities of investing in defence

According to the Institute for Economics & Peace, there are 56 active conflicts in the world, the greatest number since the end of World War II. Increasingly complex geopolitics and ReArm Europe are keeping investors on our toes, analytically.
ESG, SRI, Healthcare, Servaas Michielssens, Linden Thomson

Time to Re-engage with Healthcare?

Healthcare share prices tend to reflect some trepidation leading up to and shortly after the US presidential elections, yet for the last five elections the sector outperformed in the 12 months following the election.
ESG, SRI, Vincent Compiègne, Water

Why Water Matters: Sovereign Sustainable Investing

China dominates the entire value chain for electric transport motors. The European Union has imposed provisional tariffs to protect its regional auto industry from ‘dumping’, or unfair pricing, of subsidized electric vehicle imports from China. Yet the EU is actively attempting to accelerate the uptake of EVs to meet its 2035 emissions targets.
Alix Chosson, Elouan Heurard, ESG, SRI, Biodiversity

COP16: too little, too late.

Two years after the adoption of the Kunming-Montreal Agreement, the progress on global biodiversity goals remains mixed. Despite commitments, a limited number of countries (44 out of 196) have submitted their National Biodiversity Strategies and Action Plans. The parties have agreed to submit their plans as soon as possible, with a global review scheduled for COP17 and COP19.
ESG, SRI

Demographic Dividends: Investing in the Future

Demographic shifts, from ageing populations to rising middle classes, present long-term, diversified investment opportunities, as these structural changes are reshaping the global economy.
ESG, SRI, Oncology

Five Reasons to Invest in the Oncology Market Today

The investment landscape is evolving against a backdrop of rising economic uncertainties and a cautious market environment, further complicated by geopolitical tensions and upcoming elections.
Research Paper, ESG, SRI, Fixed Income, Dany da Fonseca, Vincent Compiègne, Patrick Zeenni

Beyond the Green Bond?

Ready for change?
Astrid Pierard, Alix Chosson, ESG, SRI, Water

Mastering the flow of water risks… A guide for investors

Les précipitations extrêmes et les sécheresses étant de plus en plus fréquentes, près de la moitié de la population mondiale est aujourd'hui confrontée à une grave pénurie d'eau pendant au moins une partie de l'année, selon les Nations unies.
Bastien Dublanc, Jessica Carlier, Astrid Pierard, Water, ESG, SRI

Forever chemicals… forever pollution?

Public awareness has risen on the risks posed by PFAS on health and on the environment. Business-wise, companies are facing increasing regulatory and market risks. Investors however should also be open to the potential opportunities offered by the PFAS market.
Fabrice Sauzeau, ESG, SRI

On the road to sustainable Solvency II

While these objectives are laudable, there are methodological obstacles. The initial objectives of Solvency II were harmonization, financial stability and policyholder protection. The text had therefore been conceived as a risk-based regulation, based on the valuation of the balance sheet on a mark-to-market basis and on capital requirements calibrated using Value at Risk (VaR) with a confidence level of 99.5%.
ESG, SRI, Circular Economy

Beyond Fossil Fuels: Why Green Investments Are Still the Future

After a challenging period for green investing, marked by rising interest rates, supply chain issues, and overcapacity, companies committed to building a sustainable world could remain an attractive long-term option for investors seeking both financial returns and positive impact.
Climate Action, ESG, SRI, Equities, US elections

2024 US Elections and Climate Policy Impact

The impact of the 2024 elections on the decarbonization theme is of paramount importance, considering that the year marks a significant electoral period globally with 64 countries and the European Union - representing nearly half of the global population - heading to the polls.
ESG, SRI, Climate Action

Scope 3 emissions data: Handle with care

In the vast subject of the challenges and difficulties of climate analysis from an investor's point of view, scope 3 emissions emerge insistently as one of the main stumbling blocks.
Patrick Zeenni, Fixed Income, ESG, SRI, Credit

A sweet spot for euro investment grade investors

After 2022, which covered the end of a decade of monetary policy loosening, 2023 has been the year of the repricing of the whole interest rate curve. The end of Central Banks’ "higher for longer" mantra supported a steepening of the yield curves and repriced real interest rates which are back now in positive territory, for the first time in close to ten years.
Research Paper, Maïa Ferrand, ESG, SRI

Investing in Natural Capital: Challenges and Opportunities

Defined as the “stock of renewable and non-renewable natural resources (e.g.,plants, animals, air, water, soils, minerals) that combine to yield a flow of benefits to people” by the Natural Capital Coalition, natural capital is at the source of everything that surrounds us.
Climate Action, ESG, SRI

COP28: Realistically optimistic?

COP28 ended with a final statement that can be considered historic, mentioning for the first time the need to transition away from fossil fuels. However, this landmark deal should be considered as the start of a more ambitious journey, that will remain dependent on governments’ ability to step up their commitments and action.
ESG, SRI, Climate Action

COP28: final countdown on climate ambitions

As the COP28 kicks off at the end of the month in Dubai, we are paying close attention to this highly anticipated event, albeit mixed expectations.
ESG, SRI, Oncology

Advances in Healthcare and Oncology: A Pink October Perspective

Good news! The five-year survival rate for women diagnosed with breast cancer in the United States is now 90%[1]. Unfortunately, when looking at other statistics, the outlook worrying: one in eight women will develop an invasive form of breast cancer during their lifetime. In 2020, two million new cancer cases were diagnosed worldwide. Breast cancer is the most common cancer type among women and the second deadliest, following lung cancer. To better understand the urgency of treatments: in 2020, 685,000 women lost their lives from breast cancer.

Find it fast

Get information faster with a single click

Get insights straight to your inbox